Skip to main content
Izotropic Corporation logo

Izotropic Corporation — Investor Relations & Filings

Ticker · IZO ISIN · CA46604F1099 LEI · 529900IZ5PIVM7X6S027 CSE Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2023-08-31 Regulatory Filings
Country CA Canada
Listing CSE IZO

About Izotropic Corporation

https://izocorp.com/

Izotropic Corporation develops and commercializes diagnostic medical devices, specializing in advanced breast cancer detection technology. Its flagship product is IzoView, a dedicated Breast CT imaging platform. IzoView utilizes high-resolution, true 3D imaging without requiring breast compression, offering superior spatial resolution compared to traditional modalities. The system is purpose-built to improve diagnostic accuracy and patient comfort, particularly targeting the 50% of women with dense breast tissue where conventional screening tools are often inadequate. Izotropic is currently advancing IzoView through pivotal clinical studies toward product launch and commercialization.

Recent filings

Filing Released Lang Actions
ON form 13-502F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 100% confidence The document is a Form 13-502F1 submission to the Ontario Securities Commission, which is a management certification related to participation fees for Class 1 and Class 3B reporting issuers. It includes detailed market value calculations and fee determinations for the reporting issuer Izotropic Corporation. The document is a regulatory filing form with officer certification and financial data related to regulatory fees, not a financial report like an annual or quarterly report. It is not an announcement or a report publication notice but a formal regulatory filing with certification. Therefore, it fits best under Regulatory Filings (RNS).
2023-08-31 English
AB form 13-501F1 (class 1 and 3B reporting issuers - participation fee).PDF
Regulatory Filings Classification · 95% confidence The document is a Form 13-501F1 Management Certification submitted to the Alberta Securities Commission. It contains a certification statement by an officer (CEO) confirming the accuracy and completeness of the information provided. The content includes market value calculations for equity securities over specified trading periods and the participation fee payable. There are no financial statements, detailed financial performance data, or management discussion and analysis. The document is primarily a certification and fee calculation form submitted for regulatory compliance purposes. It does not represent an annual report, interim report, earnings release, or any other detailed financial report. According to the Certification Rule, documents that are primarily officer certifications or attestations—even if referencing financial data—should be classified as Regulatory Filings (RNS). The document length is under 5,000 characters and is a formal certification filing rather than a report or announcement of a report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-08-31 English
Audited annual financial statements – English.pdf
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Aura Minerals Inc. about the completion of a Feasibility Study for the Borborema Project, including extensive technical and financial data such as NPV, IRR, CAPEX, production estimates, mineral resource and reserve estimates, and geological information. It references compliance with NI 43-101 standards, which is a Canadian regulatory standard for mineral project disclosure. The document is not a full annual or quarterly financial report but a technical and economic study related to a mining project. It is not a simple announcement of a report publication but contains substantive data and analysis. This type of document fits best into the category of a Capital/Financing Update (CAP) because it provides an update on a major project feasibility and ownership stake change, which impacts the company's capital allocation and future financing plans. It is not an Annual Report, Interim Report, or Earnings Release, nor is it a regulatory filing or legal proceeding. Therefore, the classification is CAP with high confidence.
2023-08-31 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a news release announcing that Izotropic Corporation has engaged a market awareness consultant to assist with communications and financing initiatives. It details the terms of the agreement, including fees and stock options, but does not contain any financial statements, earnings data, or regulatory filings. There is no indication that this is a report or a filing related to financial results, governance, or legal matters. The content is primarily an announcement about a consulting engagement related to market awareness and financing support. This fits best under the category of Capital/Financing Update (CAP), as it relates to financing initiatives and capital structure through stock options and deferred fees tied to future financing.
2023-06-27 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a news release from Izotropic Corporation announcing a modification in its FDA market approval pathway and strategy for its medical device. It discusses regulatory strategy changes, timelines, cost implications, and next steps for regulatory filings. There is no presentation of financial data, earnings, or detailed financial reports. The document is an announcement of a strategic update related to regulatory approval, not a financial report or detailed regulatory filing. It is not a certification or a report publication announcement. The content fits best under a general regulatory announcement category, as it informs investors and the public about a significant change in regulatory strategy and expected timelines. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2023-06-20 English
Material change report - English.pdf
Board/Management Information Classification · 95% confidence The document is a 51-102F3 Material Change Report filed by Izotropic Corporation. It announces a material change in the company's management: the resignation of the CEO and appointment of an interim CEO. The document includes details about the change, dates, and contact information. It is not a full annual or interim financial report, nor is it an earnings release or audit report. It is not a proxy statement or voting results announcement. The content focuses on management change, specifically the CEO resignation and appointment, which fits the category of Board/Management Information (MANG). The document length is about 5252 characters, which is sufficient for a detailed announcement but not a full financial report. Therefore, the appropriate classification is MANG with high confidence.
2023-06-12 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.